Evgen Pharma receives UK approval for breast cancer trial

Following its approval from the UK’s regulatory agency,Evgen Pharma, a clinical stage drug development company, will commence their STEM Phase II clinical trial for its breast cancer drug, SFX-01, to investigate its efficacy in combination with different hormone-based therapies, in 60 metastatic breast cancer patients, whose cancer cells are estrogen-receptor positive (ER).

Click on this link for more information.

#Pharmanews